SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: November 13, 1998
MEDIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-19131
Delaware 52-1555759
(State of Incorporation) (I.R.S. Employer
Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
No Exhibits are being filed with this report
CytoGam and RespiGam are registered trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K
ITEM 5. OTHER EVENTS
MedImmune, Inc. reported the information contained in the following press
release dated November 11, 1998:
MEDIMMUNE'S BOARD OF DIRECTORS AUTHORIZES TWO-FOR-ONE STOCK SPLIT
Gaithersburg, MD, November 11, 1998 -- MedImmune, Inc. (Nasdaq: MEDI), today
announced that its Board of Directors has voted to declare a two-for-one stock
split of the Company's common stock payable in the form of a 100 percent stock
dividend. On December 31, 1998, stockholders will receive one additional share
for every share they own as of the close of business on the record date of
December 15, 1998. As of November 10, 1998, before the effects of the stock
split, there were 27,257,763 shares outstanding.
"MedImmune's decision to split the stock reflects the significant growth in the
business and in shareholder value over the past year," commented Wayne T.
Hockmeyer, Ph.D., Chairman & Chief Executive Officer. "We also expect the split
to continue to increase liquidity in our stock and to make it attractive to a
broader group of investors."
MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products for the prevention and treatment of
infectious diseases and for use in transplantation medicine. MedImmune markets
three products through its hospital-based sales force and has four new product
candidates in clinical trials.
This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities and
Exchange Commission.
(REGISTRANT) MEDIMMUNE, INC.
BY (SIGNATURE) /s/ David M. Mott
(NAME AND TITLE) David M. Mott, Vice Chairman and Chief Financial Officer
(DATE) November 13, 1998
